Professor Mike Clarke
- Director of the Northern Ireland Clinical Trials Unit
- Northern Ireland Methodology Hub Lead, Queen’s University, Belfast
Professor Mike Clarke has nearly 30 years’ experience in the design and conduct of rigorous assessments of the effects of interventions through the use of randomised trials and systematic reviews. He joined CTSU in 1989 following a BA in chemistry and while finishing his DPhil on the history and epidemiology of suicide at the University of Oxford. Since then, he has been part of the Secretariat for the breast cancer overview, with a particular focus on the effects of ovarian ablation or suppression for women with early breast cancer. He was Director of the UK Cochrane Centre from 2002 to 2011 and now leads the Northern Ireland Methodology Hub at Queen’s University, Belfast and is Director of the Northern Ireland Clinical Trials Unit.
A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks-results from the Lassa fever pilot.
Sigfrid L. et al, (2019), BMC Med, 17
Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.
Henderson R. et al, (2019), Oncotarget, 10, 3408 - 3423
National action plans to tackle NCDs: role of stakeholder network analysis.
Hunter RF. et al, (2019), BMJ, 365
Improving the science and evidence base of disaster response: a policy research study.
Jillson IA. et al, (2019), BMC Health Serv Res, 19
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452